Enhanced cytotoxicity and apoptosis by thymoquinone in combination with zoledronic acid in hormone- and drug-resistant prostate cancer cell lines

被引:1
作者
Dirican, Ahmet [1 ]
Erten, Cigdem [1 ]
Atmaca, Harika [2 ]
Bozkurt, Emir [2 ]
Kucukzeybek, Yuksel [1 ]
Varol, Umut [1 ]
Tarhan, Mustafa Oktay [3 ,4 ]
Karaca, Burcak [5 ]
Uslu, Ruchan [5 ]
机构
[1] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Med Oncol Clin, TR-35360 Izmir, Turkey
[2] Celal Bayar Univ, Fac Sci & Arts, Dept Biol, Mol Biol Sect, Manisa, Turkey
[3] Dokuz Eylul Univ, Inst Oncol, Izmir, Turkey
[4] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, TR-35360 Izmir, Turkey
[5] Ege Univ, Tulay Aktas Oncol Hosp, Sch Med, Div Med Oncol, Izmir, Turkey
来源
JOURNAL OF BUON | 2014年 / 19卷 / 04期
关键词
apoptosis; prostate neoplasm; thymoquinone; zoledronic acid; BISPHOSPHONATES; CISPLATIN; SURVIVAL; GROWTH;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Thymoquinone (TQ), an active ingredient of black seed oil (Nigella Sativa), has been shown to possess cytotoxic activity against a variety of cancer cell lines. Our purpose was to investigate if the cytotoxic and apoptotic effect of zoledronic acid (ZA) can be enhanced by the addition of the TQ in hormone- and drug-refractory prostate cancer cells PC-3 and DU-145. Methods: XTT cell proliferation assay was used to assess cytotoxicity; DNA fragmentation and caspase 3/7 activity were also measured. Results: The combination of TQ and ZA resulted in a significant synergistic cytotoxic activity and DNA fragmentation when compared to any single agent alone, in a dose- and time-dependent manner. In addition, TQ and ZA combination increased the caspase 3/7 activity in PC-3 cell line, while this activity could not be demonstrated in DU-145 cell line. Conclusion: TQ and ZA had minimal hematological and non-hematological toxicity profile compared to cytotoxic agents. So, this combination may be an alternative approach for patients who are unable to be treated by conventional treatments because of poor performance status.
引用
收藏
页码:1055 / 1061
页数:7
相关论文
共 30 条
[1]  
Al-Shabanah OA, 1998, J EXP CLIN CANC RES, V17, P193
[2]  
[Anonymous], SEER CANC STAT REV 1
[3]   Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity [J].
Badary, OA ;
Nagi, MN ;
Al-Shabanah, OA ;
Al-Sawaf, HA ;
Al-Sohaibani, MO ;
Al-Bekairi, AM .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1997, 75 (12) :1356-1361
[4]   The influence of thymoquinone on doxorubicin-induced hyperlipidemic nephropathy in rats [J].
Badary, OA ;
Abdel-Naim, AB ;
Adel-Wahab, MH ;
Hamada, FMA .
TOXICOLOGY, 2000, 143 (03) :219-226
[5]   Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study [J].
Berthold, Dominik R. ;
Pond, Gregory R. ;
Soban, Freidele ;
de Wit, Ronald ;
Eisenberger, Mario ;
Tannock, Ian F. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :242-245
[6]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[7]   Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A [J].
Cirak, Yalcin ;
Varol, Umut ;
Atmaca, Harika ;
Kisim, Asli ;
Sezgin, Canfeza ;
Karabulut, Bulent ;
Uzunoglu, Selim ;
Uslu, Ruchan ;
Karaca, Burcak .
BJU INTERNATIONAL, 2012, 110 (11C) :E1147-E1154
[8]   Bisphosphonates: Mechanism of action and role in clinical practice [J].
Drake, Mathew T. ;
Clarke, Bart L. ;
Khosla, Sundeep .
MAYO CLINIC PROCEEDINGS, 2008, 83 (09) :1032-1045
[9]   Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells [J].
Dumon, JC ;
Journé, F ;
Kheddoumi, N ;
Lagneaux, L ;
Body, JJ .
EUROPEAN UROLOGY, 2004, 45 (04) :521-528
[10]   Combinatorial effects of thymoquinone on the anti-cancer activity of doxorubicin [J].
Effenberger-Neidnicht, Katharina ;
Schobert, Rainer .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) :867-874